vTv Therapeutics Inc. - (VTVT) News
Filter VTVT News Items
VTVT News Results
|Loading, please wait...|
Latest VTVT News From Around the Web
Below are the latest news stories about vTv Therapeutics Inc that investors may wish to consider to help them evaluate VTVT as an investment opportunity.
H.C. Wainwright analyst Vernon Bernardino reiterated a Buy rating on vTv Therapeutics (VTVT – Research Report) today and set a price target of $6.00. The company's shares closed last Wednesday at $0.84, close to its 52-week low of $0.83. According to TipRanks.com, Bernardino is a 5-star analyst with an average return of 28.0% and a 35.3% success rate. Bernardino covers the Healthcare sector, focusing on stocks such as Aridis Pharmaceuticals, Eledon Pharmaceuticals, and Citius Pharmaceuticals. Currently, the analyst consensus on vTv Therapeutics is a Moderate Buy with an average price target of $6.00. See Insiders’ Hot Stocks on TipRanks >> vTv Therapeutics' market cap is currently $75.
I hope you enjoyed the long weekend, but it's time to get back into investing with the biggest pre-market stock movers for Tuesday!
HIGH POINT, N.C., Jan. 13, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ: VTVT ), a clinical-stage biopharmaceutical company committed to improving the quality of life for people with diabetes, is sharing its updated corporate presentation highlighting its lead program TTP399, a novel oral liver-selective glucokinase activator, as a transformative treatment in the reduction of hypoglycemic episodes for the global diabetes population. Key Takeaways include: Hypoglycemia is common in people with type 1 diabetes and can occur quickly, with symptoms including sweating, nausea, coordination problems, headaches and even seizures. TTP399 may be used as a once-daily, oral adjunctive therapy in a $16B global insulin market for the reduction of hypoglycemic episodes. TTP399 has been test...
Investment company Winthrop Advisory Group LLC (Current Portfolio) buys Vanguard Extended Market Index ETF, Vanguard Intermediate-Term Corporate Bond ETF, Vanguard Tax-Exempt Bond ETF, iShares Core U.S.
Investing in the most popular stocks on the Street won't make investors rich in a few years.
vTv Therapeutics Inc (NASDAQ: VTVT ) has decided to shift focus and prioritize its lead program TTP399 as it gears up for Phase 3 pivotal trials. See the pipeline here . As a part of the restructuring, the company will reduce its workforce by approximately 65%. The company Full story available on Benzinga.com
Northern Trust Corp decreased its holdings in vTv Therapeutics Inc. (NASDAQ:VTVT) by 75.1% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 40,577 shares of the biotechnology companys stock after selling 122,545 shares during the quarter. Northern Trust Corp owned about 0.05% of 
-Workforce reduction of 65%
VTv Therapeutics Inc. said it reduced its workforce by about 65% as it prioritizes development of diabetes drug TTP399.